These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
151 related articles for article (PubMed ID: 7503183)
1. Superior compliance and efficacy of continuous combined oral estrogen-progestogen replacement therapy in postmenopausal women. Dören M; Reuther G; Minne HW; Schneider HP Am J Obstet Gynecol; 1995 Nov; 173(5):1446-51. PubMed ID: 7503183 [TBL] [Abstract][Full Text] [Related]
2. Long-term compliance of continuous combined estrogen and progestogen replacement in postmenopausal women. Dören M; Schneider HP Maturitas; 1996 Oct; 25(2):99-105. PubMed ID: 8905600 [TBL] [Abstract][Full Text] [Related]
3. Transdermal estrogen with a levonorgestrel-releasing intrauterine device for climacteric complaints: clinical and endometrial responses. Raudaskoski TH; Lahti EI; Kauppila AJ; Apaja-Sarkkinen MA; Laatikainen TJ Am J Obstet Gynecol; 1995 Jan; 172(1 Pt 1):114-9. PubMed ID: 7847516 [TBL] [Abstract][Full Text] [Related]
4. Effects of a continuous estrogen-progestogen therapy for climacteric symptoms on circulating sex steroids and gonadotrophins. Mattsson LA; Abrahamsson L; Cullberg G; Samsioe G Arch Gynecol; 1983; 233(2):101-7. PubMed ID: 6683955 [TBL] [Abstract][Full Text] [Related]
5. Continuous versus cyclical transdermal estrogen replacement therapy in postmenopausal women: influence on climacteric symptoms, body weight and bleeding pattern. Lübbert H; Nauert C Maturitas; 1997 Dec; 28(2):117-25. PubMed ID: 9522319 [TBL] [Abstract][Full Text] [Related]
6. Endometrial safety and tolerability of triphasic sequential hormone replacement estradiol valerate/medroxyprogesterone acetate therapy regimen. Rees MC; Kuhl H; Engelstein M; Mattila L; Mäenpää J; Mustonen M; Climacteric; 2004 Mar; 7(1):23-32. PubMed ID: 15259280 [TBL] [Abstract][Full Text] [Related]
7. Effect of combined oral estrogen/progestogen preparation (Kliogest) on bone mineral density, plasma lipids and postmenopausal symptoms in HRT-naïve Thai women. Jirapinyo M; Theppisai U; Manonai J; Suchartwatnachai C; Jorgensen LN Acta Obstet Gynecol Scand; 2003 Sep; 82(9):857-66. PubMed ID: 12911449 [TBL] [Abstract][Full Text] [Related]
8. Bleeding patterns during continuous combined estrogen-progestogen therapy. Marslew U; Riis BJ; Christiansen C Am J Obstet Gynecol; 1991 May; 164(5 Pt 1):1163-8. PubMed ID: 1827947 [TBL] [Abstract][Full Text] [Related]
9. [Basic principles of hormone replacement therapy in the postmenopause]. Dören M Ther Umsch; 2000 Oct; 57(10):628-34. PubMed ID: 11081374 [TBL] [Abstract][Full Text] [Related]
10. Bleeding pattern and climacteric symptoms during different sequential combined HRT regimens in current use. Marslew U; Munk-Nielsen N; Nilas L; Riis BJ; Christiansen C Maturitas; 1994 Oct; 19(3):225-37. PubMed ID: 7799829 [TBL] [Abstract][Full Text] [Related]
11. Estrogen-progestogen replacement in climacteric women, particularly as regards a new type of continuous regimen. Mattsson LA; Samsioe G Acta Obstet Gynecol Scand Suppl; 1985; 130():53-8. PubMed ID: 3859976 [TBL] [Abstract][Full Text] [Related]
12. Estrogen-progestogen replacement therapy in postmenopausal women--is 1 mg estradiolvalerate sufficient to maintain axial trabecular bone density? Dören M; Schneider HP Int J Clin Pharmacol Ther; 1994 May; 32(5):254-8. PubMed ID: 7921520 [TBL] [Abstract][Full Text] [Related]
13. Two new combinations of estrogen and progestogen for prevention of postmenopausal bone loss: long-term effects on bone, calcium and lipid metabolism, climacteric symptoms, and bleeding. Marslew U; Overgaard K; Riis BJ; Christiansen C Obstet Gynecol; 1992 Feb; 79(2):202-10. PubMed ID: 1309944 [TBL] [Abstract][Full Text] [Related]
14. Five years with continuous combined oestrogen/progestogen therapy. Effects on calcium metabolism, lipoproteins, and bleeding pattern. Christiansen C; Riis BJ Br J Obstet Gynaecol; 1990 Dec; 97(12):1087-92. PubMed ID: 2126198 [TBL] [Abstract][Full Text] [Related]
15. Continuous combined conjugated equine estrogen-progestogen therapy: effects of medroxyprogesterone acetate and norethindrone acetate on bleeding patterns and endometrial histologic diagnosis. Hillard TC; Siddle NC; Whitehead MI; Fraser DI; Pryse-Davies J Am J Obstet Gynecol; 1992 Jul; 167(1):1-7. PubMed ID: 1442905 [TBL] [Abstract][Full Text] [Related]
16. Modulation by progestogens of the effects of oestrogen on hepatic endocrine function in postmenopausal women. Nugent AG; Leung KC; Sullivan D; Reutens AT; Ho KK Clin Endocrinol (Oxf); 2003 Dec; 59(6):690-8. PubMed ID: 14974909 [TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of oral estriol for managing postmenopausal symptoms. Takahashi K; Manabe A; Okada M; Kurioka H; Kanasaki H; Miyazaki K Maturitas; 2000 Feb; 34(2):169-77. PubMed ID: 10714912 [TBL] [Abstract][Full Text] [Related]
18. [Effect and tolerability of sequential administration of estradiol valerate and medroxyprogesterone acetate on menopausal symptoms, hormonal profile and biochemical markers in climacteric women]. Radowicki S; Skórzewska K; Borakowska B; Wierzba W; Michalewski K Ginekol Pol; 2004 Jan; 75(1):39-46. PubMed ID: 15112472 [TBL] [Abstract][Full Text] [Related]
19. Optimizing continuous-combined hormone replacement therapy for postmenopausal women: a comparison of six different treatment regimens. Heikkinen JE; Vaheri RT; Ahomäki SM; Kainulainen PM; Viitanen AT; Timonen UM Am J Obstet Gynecol; 2000 Mar; 182(3):560-7. PubMed ID: 10739508 [TBL] [Abstract][Full Text] [Related]
20. Comparison of continuous and sequential transdermal progestogen with sequential oral progestogen in postmenopausal women using continuous transdermal estrogen: vasomotor symptoms, bleeding patterns, and serum lipids. Rozenberg S; Ylikorkala O; Arrenbrecht S Int J Fertil Womens Med; 1997; 42 Suppl 2():376-87. PubMed ID: 9397385 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]